Carbetocin
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphagia in Prader-Willi Syndrome
Conditions
Hyperphagia in Prader-Willi Syndrome
Trial Timeline
Mar 11, 2024 → Jun 1, 2029
NCT ID
NCT06420297About Carbetocin
Carbetocin is a phase 3 stage product being developed by Acadia Pharmaceuticals for Hyperphagia in Prader-Willi Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06420297. Target conditions include Hyperphagia in Prader-Willi Syndrome.
What happened to similar drugs?
0 of 3 similar drugs in Hyperphagia in Prader-Willi Syndrome were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06420297 | Phase 3 | Recruiting |
Competing Products
3 competing products in Hyperphagia in Prader-Willi Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carbetocin + Placebo | Acadia Pharmaceuticals | Phase 3 | 41 |
| Placebo + ARD-101 | Aardvark Therapeutics | Phase 3 | 34 |
| ARD-101 | Aardvark Therapeutics | Phase 3 | 34 |